In both mice (1, 2) and humans (3) there is a strong inverse relation between the blood levels of HDL and the development of atherosclerosis. The atheroprotective effect of HDL is ascribed to its role in reverse cholesterol transport (RCT), as first proposed by Glomset (4), in which HDL accepts cholesterol from peripheral cells, including those in the arterial wall, and delivers it to the liver for biliary secretion (reviewed in Refs. 4-10). In addition, HDL can deliver its cholesteryl ester (CE) to the adrenals and testis or ovary for steroid hormone synthesis (11, 12) . At both the liver and steroidogenic tissues, cholesterol delivery occurs via selective cellular uptake of HDL-CE without stoichiometric degradation of HDL protein (13, 14) . Acton and coworkers (15) provided the first evidence that scavenger receptor class B type I (SR-BI) can mediate the selective uptake of HDL-CE in Chinese hamster ovary cells stably transfected with mouse SR-BI. Furthermore, treatment of the adrenocortical cell line Y1-BS1 with antibodies directed against mouse SR-BI resulted in a dramatic decrease in the selective uptake of HDL-CE (16).
In both mice (1, 2) and humans (3) there is a strong inverse relation between the blood levels of HDL and the development of atherosclerosis. The atheroprotective effect of HDL is ascribed to its role in reverse cholesterol transport (RCT), as first proposed by Glomset (4) , in which HDL accepts cholesterol from peripheral cells, including those in the arterial wall, and delivers it to the liver for biliary secretion (reviewed in Refs. [4] [5] [6] [7] [8] [9] [10] . In addition, HDL can deliver its cholesteryl ester (CE) to the adrenals and testis or ovary for steroid hormone synthesis (11, 12) . At both the liver and steroidogenic tissues, cholesterol delivery occurs via selective cellular uptake of HDL-CE without stoichiometric degradation of HDL protein (13, 14) . Acton and coworkers (15) provided the first evidence that scavenger receptor class B type I (SR-BI) can mediate the selective uptake of HDL-CE in Chinese hamster ovary cells stably transfected with mouse SR-BI. Furthermore, treatment of the adrenocortical cell line Y1-BS1 with antibodies directed against mouse SR-BI resulted in a dramatic decrease in the selective uptake of HDL-CE (16) .
In vivo, the expression levels of rat and mouse SR-BI mRNA and protein are highest in liver and steroidogenic tissues (adrenal gland, testis, and ovary) (17, 18) , all tissues that display selective uptake of HDL-CE. We showed earlier (19) that changes in SR-BI expression in rat liver, induced by estradiol treatment or a high-cholesterol diet, correlated with changes in the selective uptake of HDL-CE in vivo, supporting a function of SR-BI in mediating the selective uptake of HDL-CE. Adenovirus-mediated hepatic overexpression of SR-BI in mice on both sinusoidal and canalicular surfaces of hepatocytes resulted in the virtual disappearance of plasma HDL and a substantial increase in biliary cholesterol (20) . A similar decrease in plasma HDL cholesterol levels was found in transgenic mice overexpressing SR-BI under the control of the apolipoprotein A-I promoter (21) . These studies indicated that SR-BI expression in the liver can regulate blood HDL me-tabolism and influence cholesterol secretion into bile. Studies with transgenic mice with liver-specific overexpression of SR-BI showed increased total and selective uptake of HDL-CE by the liver compared with nontransgenic controls (22, 23) . In addition, in SR-BI attenuate (att) mice with an SR-BI promoter mutation resulting in decreased expression of the receptor, the hepatic uptake of HDL-CE was decreased accordingly (24) . Further evidence for the role of SR-BI in RCT was provided by studies in SR-BI knockout (KO) mice. These animals displayed impaired biliary cholesterol secretion (25, 26) and increased plasma cholesterol concentration in large apolipoprotein A-I-containing particles, together with low adrenal gland cholesterol content (27, 28) .
Although the aforementioned studies are consistent with a regulatory role of SR-BI in HDL metabolism, there is no report that addresses the quantitative contribution of SR-BI in vivo to the selective uptake of HDL-CE by the liver and the adrenals. By using SR-BI KO mice in the present study, we made a quantitative comparison of the metabolism of HDL-CE in SR-BI KO and wild-type (WT) mice to assess the contribution of SR-BI to the serum decay and hepatic and adrenal uptake of HDL-CE. The data obtained are compared with data for holo-particle uptake, determined by analyzing the fate of 125 I-tyramine-cellobiose-labeled HDL ([ 125 I]TC-HDL) in the animals, to assess whether additional HDL binding proteins perform selective CE uptake from HDL. In addition, studies with isolated parenchymal liver cells from WT and SR-BI KO mice demonstrate the quantitative importance of SR-BI for the high level of selective uptake of HDL-CE by these cells.
MATERIALS AND METHODS
Egg yolk phosphatidylcholine was from Fluka (Buchs, Switzerland). Cholesteryl [ 
, and 125 I (carrier free in NaOH) were obtained from Amersham (Piscataway, NJ). The PL phospholipids kit, the CHOD-PAP (cholesterol oxidase-peroxidase aminophenazone) kit, and the GPO-PAP (glycerolphosphate oxidaseperoxidase aminophenazone) kit were from Roche Diagnostics (Mannheim, Germany). Hypnorm and Thalamonal were from Janssen Pharmaceutica (Titusville, NJ), and ketamine was from BelaPharm (Vechta, Germany). Ethylmercurithiosalicylate (thimerosal), BSA (fraction V), and collagenase type IV were from Sigma-Aldrich (St. Louis, MO). DMEM was from BioWhittaker (Walkersville, MD). All other chemicals were of analytical grade.
Animals
Heterozygous srbI ϩ / Ϫ mice on a 129(agouti)/C57BL/6 background were kindly provided by Dr. Monty Krieger (Massachusetts Institute of Technology). The offspring of these mice was analyzed by polymerase chain reaction as described (27) for the presence of the targeted or WT SR-BI alleles. Experiments were carried out with homozygous mutant ( srbI Ϫ / Ϫ ) progeny. The WT ( srbI ϩ / ϩ ) littermates were used as controls. All animals used were between 8 and 10 week old males. Animals were maintained on a 12 h light/dark cycle and had unlimited access to regular chow diet (SRM-A; Hope Farms, Woerden, The Netherlands) and water. Animal welfare was in accordance with institutional guidelines.
Phospholipid liposome preparation
Unilamellar liposomes were prepared from egg yolk phosphatidylcholine and labeled with [ 3 H]CEt or [ 3 H]CE as described (29) .
Isolation and labeling of lipoproteins
Human HDL and LDL were isolated from blood of healthy subjects by differential ultracentrifugation as described by Redgrave, Roberts, and West (30) (33) . To 50 l of 0.3 mM [ 125 I]TC were successively added 20 l of 0.75 mM cyanuric chloride in acetone and 10 l of 3.0 mM NaOH. After 20 s, 20 l of 2.25 mM acetic acid was added. The resulting activated ligand was added to 1-2 mg of HDL in 1 ml of 20 mM sodium tetraborate buffer, pH 9.0, containing 0.12 M NaCl and 1 mM EDTA. After 30 min at room temperature, the reaction was quenched by the addition of an equal volume of 0.2 M NH 4 HCO 3 . Unbound label was removed by exhaustive dialysis against phosphate-buffered saline (10 mM sodium phosphate buffer, pH 7.4, containing 150 mM NaCl and 1 mM EDTA). Less than 1% of the labeled material was trichloroacetic acid soluble. The specific activity was 20-30 cpm/ng protein. Before use, the radiolabeled HDL was checked for hydrolysis of the CE label and for its composition and physical properties (29) . Hydrolysis of the CE was Ͻ 5%. Labeled HDL was used only when there were no differences in physical behavior and composition compared with the unlabeled HDL.
LDL was dialyzed against PBS with 10 M EDTA and, where indicated, oxidized by exposure to CuSO 4 as described (34) .
Plasma decay, organ association, and liver cell distribution
A dose of 200 g (apolipoprotein) Ϯ 1.2 ϫ 10 6 dpm (plasma decay and organ association) or 500 g (apolipoprotein) Ϯ 3 ϫ 10 6 dpm (liver cell distribution) of [ 3 H]CEt-HDL (total volume of 100 or 250 l) was injected into the tail vein of WT and SR-BI KO mice. At 3 min after injection, a blood sample was drawn to verify the injected dose. At the indicated time points, blood samples were drawn to measure serum decay. For analysis of organ association, the liver, adrenals, and various other organs (stomach, intestines, thymus, pancreas, spleen, kidneys, thyroid, heart, aorta, veins, lungs, lymph nodes, muscles, skin, adipose tissue, bones, and reproductive organs) were isolated for radioassay at 1, 2, 4, and 24 h after tracer injection. The organs were weighed, solubilized, and counted for 3 H radioactivity in a Packard liquid scintillation unit and for 125 I in a ␥ counter (Packard). Correction was made for the radioactivity in the blood present in the organs at the time of sampling as determined by injection of screened at PENN STATE UNIVERSITY, on February 23, 2013 www.jlr.org Downloaded from
The values are in l/g organ (means Ϯ SEM; n ϭ 4): liver, 84.7 Ϯ 8.9; heart, 68.1 Ϯ 2.9; lung, 125.9 Ϯ 13.2; stomach, 22.9 Ϯ 3.2; kidney, 135.2 Ϯ 7.2; adrenal, 110.2 Ϯ 9.5; spleen, 64.6 Ϯ 9.1; small intestine, 46.3 Ϯ 9.0; large intestine, 35.2 Ϯ 3.0; skin, 13.1 Ϯ 3.4; muscle, 13.7 Ϯ 2.5; and bone, 30.1 Ϯ 5.2.
When double-labeled HDL was used, the [ 3 H]CEt radioactivity was measured in a Packard ␤ counter with a double label program. Within the used 3 H/ 125 I activity ratios the percentage recovery for 3 H is 100 Ϯ 2%. Computer analysis using an interactive curve peeling program was applied to fit a least-squares multiexponential curve to each set of serum decay data and to calculate fractional catabolic rates (FCRs) according to the model of Matthews (35) . The uptake by liver parenchymal, endothelial, and Kupffer cells was determined at 2 h after injection. After a liver lobule was tied off (total liver sample), the parenchymal liver cells were isolated as indicated under In Vitro Studies with Freshly Isolated Hepatocytes. The endothelial and Kupffer cells were collected from the parenchymal cell supernatant by centrifugation for 10 min at 500 g and separated further via centrifugal elutriation as described (36) . The purity of each fraction was examined via a staining reaction for peroxidase activity followed by light microscopy. The purity was 80-90% and Ͼ 95% for Kupffer cells and endothelial cells, respectively. The total liver sample and the cell isolations were solubilized and analyzed for protein content and radioactivity.
Protein determination
Protein was determined according to Lowry et al. (37) with BSA as the standard.
In vitro studies with freshly isolated hepatocytes
Between 10 and 11 AM, WT ( srbI ϩ / ϩ ) and SR-BI KO ( srbI Ϫ / Ϫ ) mice were anesthetized by subcutaneous injection with a mixture of 1.5% (w/v) ketamine, 8.5% (v/v) Thalamonal, and 1.5% (v/v) Hypnorm in PBS at a dose of 5-7.5 ml/kg. Collagenase perfusion [0.06% (w/v) collagenase] of the liver was then performed for 12 min as described (38) . Liver cells were collected by mincing the liver in ice-cold Hank's buffer containing 0.3% (w/v) BSA followed by filtration through nylon gauze to remove large debris. Three subsequent washing steps (10 min, 50 g , 4 Њ C) with ice-cold Hank's buffer were performed to separate the parenchymal cells (pellet) from the endothelial and Kupffer cells (supernatant). The pellet consisted of pure parenchymal cells as judged by light microscopy. Cell viability was examined by trypan blue exclusion and was 80-90% in every case. After resuspension in oxygenated DMEM supplemented with 2% (w/v) BSA (pH 7.4), 1 mg of parenchymal cell protein was incubated with the indicated amounts of ligand at 37 Њ C for 3 h in a final volume of 0.5 ml. During the incubation, the cells were shaken at 150 rpm and briefly oxygenated every hour. The viability of the cells remained greater than 80% during these incubations. Subsequently, the cells were washed twice with wash buffer (0.15 M NaCl, 2.5 mM CaCl 2 , and 50 mM Tris-HCl, pH 7.4) containing 0.2% (w/v) BSA and once with the same buffer without BSA, after which the cells were lysed in 0.1 N NaOH and protein content and radioactivity were measured.
RESULTS

Serum decay and liver and adrenal association
Upon injection of [ 3 H]CEt-HDL into WT mice, 51.7 Ϯ 3.1% of the injected label was removed from the blood during the first 4 h. In SR-BI KO mice, a severely delayed clearance was noted ( Fig. 1 ) . In WT mice, the liver uptake of CEt from HDL increased gradually up to 4 h after injection. At this time point, 31.3 Ϯ 4.9% of the injected dose (ID) was recovered in the liver (Fig. 1) . This indicates that, in agreement with data obtained in rats (30) , also in mice the liver is responsible for the majority of the removal of CEt from HDL. In SR-BI KO mice, the liver uptake of CEt from HDL was greatly diminished: at 4 h after injection, only 3.3 Ϯ 0.8% of the ID accumulated in the liver, indicating an almost 90% inhibition of liver uptake in the absence of SR-BI ( P Ͻ 0.05). Serum decay kinetics and the rate at which the liver accumulated CEt tracer were determined in both WT and SR-BI KO mice. The activity of the liver was expressed as organ FCR per gram of tissue. This represents the fraction of the plasma pool of the traced HDL component cleared per hour per gram of tissue. The serum decay rate and the liver FCR of the [ 3 H]CEt-HDL were higher in WT mice compared with SR-BI KO mice. In WT mice, the serum FCR was 0.106 Ϯ 
serum pools/h/g in KO mice (P ϭ 0.036). These values indicate a severely delayed capacity for CE uptake in the SR-BI KO mice.
We observed earlier that SR-BI deficiency induced a 1.8-fold increase in total serum cholesterol levels (28) . Interestingly, this increase in total cholesterol levels was mainly the result of a 3.2-fold increase in free cholesterol, and CEs were only increased by 1.3-fold. Rigotti et al. (27) reported that apolipoprotein A-I levels were not different between WT and SR-BI KO mice. Correction for the HDL-CE pool size indicates that the HDL-CE mass influx into the liver was reduced from 22.0 Ϯ 3.8 g HDL-CE/h in WT mice to 4.1 Ϯ 0.7 g HDL-CE/h in SR-BI KO animals. To verify the possible presence of a selective CE decay and uptake in the absence of SR-BI, we injected doublelabeled HDL, whereby the protein moiety was additionally labeled with [ 125 I]TC (Fig. 2, Table 1) . In WT mice, the decay rate of 4% for KO mice) indicated that no residual selective uptake of CE from HDL was observed in SR-BI KO mice. Because the observed liver uptake did not account fully for the serum decay, the distribution of radioactivity over extrahepatic tissues was also analyzed at various time points after injection; the data for 24 h are given in Table 2 . It was found that the majority of the extrahepatic label was present in skin (15-18%), bones (6-8%), muscle (3%), and intestine (4%), whereas the other tissues contained Ͻ1% for each tissue. The total recovery of label was between 80% and 90% for both WT and KO mice in every case. There was no significant difference in extrahepatic distribution between WT and SR-BI KO animals except for the adrenals. The major differences in adrenal uptake occurred during the first 4 h after injection (Fig. 1) , during which the uptake in WT mice increased to 45.3 Ϯ 5.0% of the ID/mg wet weight ϫ 10 3 , whereas uptake was only 6.3 Ϯ 1.1% of the ID/mg wet weight ϫ 10 3 in the SR-BI KO mice (Table 1) .
In vivo liver cell distribution
At 2 h after injection of [ 3 H]CEt-HDL, parenchymal, endothelial, and Kupffer cells were isolated from the livers of WT and SR-BI KO mice to examine the potential roles of SR-BI in the process of CEt uptake by these various cell types. For total liver, there was an 81.6% lower association of CEt in SR-BI KO animals compared with WT mice (13.1 Ϯ 1.3% and 71.3 Ϯ 3.6% of the ID/mg protein ϫ 10 Ϫ3 for KO and WT mice, respectively) (Fig. 3) . It can be calculated that in the WT liver, parenchymal cells were responsible for 88% of the [ 3 H]CEt uptake from HDL, when taking into account the contribution of these cells to total liver mass. The absence of SR-BI from the liver parenchymal cells resulted in an 87% decrease of CEt uptake (62.4 Ϯ 1.1% uptake of the ID/g protein ϫ 10 Ϫ3 in WT parenchymal cells vs. 8.0 Ϯ 0.6% uptake of the ID/mg protein ϫ 10 Ϫ3 in SR-BI KO parenchymal cells). For liver endothelial cells, no significant difference was observed. In the Kupffer cell fraction from SR-BI KO mice, the uptake of CEt from HDL was 51.5% lower compared with WT mice (69.6 Ϯ 13.9% and 143.4 Ϯ 7.5% of the ID/mg protein ϫ 10 Ϫ3 , respectively). Because parenchymal liver cells are the predominant cell type in the liver (92.5%), the diminished uptake of CEt by the SR-BI KO liver is mainly the consequence of the absence of SR-BI in the parenchymal liver cells and is only to a minor extent caused by the SR-BI deficiency in the Kupffer cells.
In vitro parenchymal liver cell association
Parenchymal liver cells from WT and SR-BI KO mice were isolated and incubated for 3 h at 37ЊC with different concentrations of HDL doubly labeled with [ 3 H]CE and [ 125 I]TC. As described by Pittman et al. (39) , values for CE association are expressed in terms of apparent particle uptake (i.e., from the amount of 3 H-labeled tracer associated with the cells, the amount of HDL protein apparently taken up is calculated). In WT parenchymal liver cells, the CE association increased with increasing ligand concentration and exceeded the association to SR-BI KO cells by ‫-3ف‬ to 5-fold (Fig. 4) . In SR-BI KO parenchymal liver cells, at every ligand concentration used, the association of HDL-derived [ 3 H]CE was similar to the [ 125 I]TC association, indicating that SR-BI KO parenchymal liver cells performed no residual selective CE uptake from HDL (Fig. 4) 
Effect of LDL and oxidized LDL on selective uptake of [ 3 H]CE from HDL
Previously, we had shown that oxidized LDL (oxLDL) is a very potent inhibitor of HDL-CE association with rat parenchymal liver cells. Based on these inhibition characteristics, we suggested that SR-BI mediates the efficient uptake of HDL-CE by these cells (28) . In the present study, the availability of SR-BI KO mice enabled us to determine if this assumption is true. Incubation of freshly isolated WT and SR-BI KO mouse parenchymal liver cells with 10 g/ml [ 3 H]CE-HDL for 3 h at 37ЊC resulted in an association of 476.3 Ϯ 37.8 ng/mg cell protein for WT cells and a 5-fold lower association of 89.5 Ϯ 18.9 ng/mg cell protein for SR-BI KO cells (Fig. 5) . The efficiency of modified LDL to compete for this [ 3 H]CE-HDL association was examined by including the indicated amounts of unlabeled native or oxidized LDL in the incubation (Fig. 5) . Addition of native LDL only marginally decreased the cell association (18% in WT cells and 20% in SR-BI KO cells at the highest concentration of 100 g/ml). Competition with oxLDL at a concentration of 100 g/ml resulted in a 73% reduction of [ 3 H]CE-HDL cell association to WT cells. With an ox-LDL concentration as low as 25 g/ml, a 52% decrease was achieved (Fig. 5) . In contrast, in the SR-BI KO parenchymal liver cells, oxLDL did not efficiently decrease the association of [ 3 H]CE-HDL. This indicates that apparently oxLDL is a very efficient inhibitor of the SR-BI-mediated selective uptake of CE from HDL.
DISCUSSION
Selective delivery of CE from HDL to the adrenals and the liver is important for the supply of substrate for steroid hormone synthesis and the maintenance of lipid homeostasis, respectively. Based on the following evidence, SR-BI is suggested to be a functional receptor for HDL: i) SR-BI is highly expressed in the steroidogenic organs and the liver in rats (17) and mice (18) ; ii) SR-BI can bind HDL via interaction with its apolipoproteins (40) ; and iii) SR-BI can mediate the selective uptake of HDL-CE (15) . In the present work, we used SR-BI KO mice to assess the quantitative role of SR-BI in the selective uptake of CE from HDL in vivo by comparing the uptake in these animals with that in WT mice. Our data show that, in the intact animal, the initial rate at which CE is taken up from HDL by the liver and the adrenals is greatly diminished in SR-BI KO animals compared with WT animals. Calculation of the liver FCR for WT and KO animals indicated that CE uptake from HDL by the liver occurred eight times faster in WT animals. This shows the quantitative importance of SR-BI as a rate-limiting factor in the process of selective uptake of CE from HDL by the liver. It is consistent with the finding that in SR-BI KO mice biliary cholesterol secretion is impaired (25, 26) and that plasma HDL cholesterol concentrations are increased by 125% (27) . In agreement with the rate-determining role of SR-BI in the selective CE uptake from HDL, it has been reported that overexpression of SR-BI in vivo resulted in a dramatic decrease in plasma HDL cholesterol levels (20) (21) (22) and increased total and selective uptake of HDL-CE by the liver (22) compared with nontransgenic controls. Furthermore, our data are consistent with the decreased CE uptake from HDL by the liver observed in SR-BI att mice, which have an attenuated expression of the SR-BI receptor (24) . Analysis of the organ distribution of [ 3 H]CE at various times after injection indicated that in addition to the liver, only the uptake by the adrenals is impaired in the absence of SR-BI. This is in accordance with the previously reported low adrenal gland cholesterol content in homozygous SR-BI KO mice (27) . Comparison of the uptake values obtained for [ 3 H]CE and [ 125 I]TC, a nondegradable and accumulating label located in the protein moiety of HDL, indicates that in SR-BI KO mice the residual CE uptake can be ascribed to HDL holo-particle association and/or uptake. This implies not only that SR-BI is the determining factor for the selective uptake of CE from HDL but also that no additional routes for the selective uptake of CE from HDL are active in vivo. Our data obtained with SR-BI KO animals compared with WT mice thus form the final proof that SR-BI is solely responsible for the selective uptake of CE from HDL in the blood circulation by the liver and the adrenals.
Recently, in a preliminary report, Rinninger's group (41) came to the same conclusion by studying the kinetics of autologous HDL in SR-BI KO mice.
The liver does contain, in addition to the parenchymal cells, endothelial and Kupffer cells. We have shown previously (19) that, in rats, SR-BI protein is expressed in both the parenchymal and Kupffer cells. Treatment with estradiol or a high-cholesterol diet led to downregulation of SR-BI protein expression in the parenchymal cells and resulted in an upregulation of SR-BI protein expression in the Kupffer cells. These changes in SR-BI protein expression correlated with changes in the ability of these cells to perform selective uptake of CE from HDL (19) . In the present study, isolation of parenchymal, endothelial, and Kupffer cells at 2 h after in vivo administration of [ 3 H]CEt-HDL revealed that in the SR-BI KO mice CEt-HDL uptake is greatly impaired in parenchymal cells but in liver endothelial cells no difference in uptake of CEt from HDL was observed. Kupffer cells from SR-BI KO mice showed a 2-fold decrease in CE uptake from HDL compared with WT mice. These data obtained in mice are consistent with our earlier data for the rat. Because the parenchymal liver cells account for 92.5% of total liver protein, we conclude that the SR-BI-mediated selective uptake of CE from HDL by the liver is mainly exerted by the parenchymal cells.
In view of the major role of the parenchymal liver cells in the removal of CE from HDL, additional in vitro studies were performed with these cells from WT and SR-BI KO mice. Pioneering studies by Glass and coworkers (11, 14) have shown that the uptake route of HDL-CE by liver parenchymal cells is characterized by the selective uptake of the CE without simultaneous uptake of the holo-particle. We have shown previously that the selective uptake of HDL-CE by rat parenchymal liver cells can be blocked efficiently by oxLDL (29) and also that changes in SR-BI protein expression, induced by a high-cholesterol diet or estradiol treatment, correlated with changes in the selective uptake of HDL-CE in vitro (19) . Our present data with isolated parenchymal liver cells from SR-BI KO mice indicate that the uptake of HDL-CE is greatly diminished compared with WT parenchymal liver cells and also that inhibition by oxLDL of the selective uptake process no longer occurs. This indicates that, similar to the in vivo observations, SR-BI expression is essential for the efficient uptake of CE from HDL. In addition, the present data support our earlier suggestion (29) that the inhibition of CE uptake from HDL by oxLDL indicates that SR-BI is mainly responsible for the selective uptake process. By simultaneous measurement of [ 3 H]CE uptake and [ 125 I]TC uptake (reflecting holo-particle uptake) from HDL in parenchymal cells from SR-BI KO mice, we conclude that these cells, in contrast to WT parenchymal liver cells, no longer exert selective CE uptake from HDL. These data are consistent with the in vivo uptake values and indicate that for this major liver cell type SR-BI is essential for the selective uptake of CE from HDL. Furthermore, the data indicate that the parenchymal liver cells do not contain additional receptor systems that can facilitate this unique uptake route.
In conclusion, both our in vivo and in vitro data prove that SR-BI is mainly responsible for the efficient and selective uptake of HDL-CE by the liver and the adrenals, making it an important target for pharmaceutical interference with the RCT process. 
